Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

By J. Shapiro, J. V. van Lanschot, M. Hulshof, P. van Hagen, M. I. van Berge Henegouwen, B. Wijnhoven, H. V. van Laarhoven, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp and 20 more. The Lancet Oncology, 2015

2,170 citations recorded by the source corpus.

Subfields: Otorhinolaryngology, Surgery

View Paper: https://www.semanticscholar.org/paper/c0c04b3a8b9980cde3c290f28ae09e40e28b5920

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. X. D’Journo
2. Yu-ping Chen
3. Hui Liu
4. Yongtao Han
5. J. Xiang
6. Baofu Chen
7. A. Brunelli
8. W. Mao

Citations in the corpus

• Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial (2018, background): “The sample size of ESCC was relatively small in most trials(5-11); there were usually no more than 80 cases of patients with ESCC receiving NCRT in each study.(5-13) Whether the results could be applied to East Asian countries such as China where the incidence of ESCC is extremely high remains to be”